Men with diabetes have an increased risk for erectile dysfunction (ED) than those without diabetes. The diabetes control and complications trial clearly showed that better long-term control of blood glucose in diabetes type 1 is associated with decreased frequency and delayed the onset of microvascular complications. The aim of this study is to explore the role of glycemic control, and its correlation to sexual function in patients with diabetes type 2. One hundred patients were selected for the study according to the following criteria: all the cases were presenting with diabetes type 2 as a single risk factor for ED, age being between 35 and 50 years and free of liver and kidney failure, and blood dyscrasis. The selected patients were evaluated for sexual function by asking the patients to complete the abridged form of the International Index of Erectile Function (IIEF). The evaluation of glycemic control was based on the measurement of hemoglobin A 1c (HbA 1c ) values. Our results showed that the level of HbA 1c is significantly higher with declining degrees of potency (P-value ¼ 0.003). Also, there is an association between potency degree and glycemic control (P ¼ 0.002). We conclude that glycemic control is independently and inversely associated with ED in men with diabetes type 2.
Introduction
Erectile dysfunction (ED) is common in men with diabetes, with a prevalence of 20 to 85%. 1 Men with diabetes have a threefold increased risk for ED compared with those without diabetes. Furthermore, ED has been found to be age dependent and is accelerated in age-matched diabetic males. ED affects those with diabetes an average 10-15 years earlier than the general population regardless of the insulin dependency status. 2 In diabetic men, Ed may be multifactorial in origin, involving possible vascular, neurological and endocrinological components. 3 In addition, individuals with diabetes may have other comorbid conditions that are associated with erectile dysfunction without diabetes, such as renal failure, hypertension and chronic liver disease, making the precise association of diabetes with ED circumstantial under these conditions. 4 Glycemic control is a factor associated with endorgan complications of diabetes. The diabetes control and complications trial clearly showed that better long-term control of blood glucose in diabetes type 1 is associated with decreased frequency and delayed onset of microvascular complications. 5 Our aim was to explore the role of glycemic control, and its correlation to sexual function in patients with diabetes type 2.
Patients and methods
This study included 100 male diabetic patients. Our study has the approval of an Ethics Committee.
All the patients were subjected to the following:
Complete personal history. Examination: Complete general and genital examination. Laboratory tests: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, Bilirubin level both total and direct, blood urea nitrogen, creatinine, blood dyscrasis and dyslipidemia were performed for the patients.
Patients were selected according to the following criteria: All patients presenting with diabetes type 2 (non-insulin dependent diabetes mellitus or late onset diabetes). 6 Age group between 35-50 years. Patients have negative assessments for liver failure, kidney failure, blood dyscrasis or hyperlipidemia and having no other risk factors for sexual dysfunction (smoking, drug abuse, hypertension, obesity and bicycling).
All the patients were subjected to:
Evaluation of the sexual function. This was performed by asking the patients to complete questions from the International Index of Erectile Function questionnaire.
7 Questions 1-5 were used to assess the erectile function as recommended by Romeo et al. (2000) , 8 who described it to be a reliable measure for erectile function. The outcome measure was erectile function score, calculated as the sum of questions 1-5 from the International Index of Erectile Function with a maximum score of 25.
Results obtained were classified as described by Resen et al. (1997) 7 as follows: good response, (420); fair response (15) (16) (17) (18) (19) (20) ; and poor response (o15).
Glycemic control evaluation. The evaluation of glycemic control was based on the measurement of Hemoglobin A 1c (HbA 1c ) values, which evaluated control through the last 3 months. 9 The method used for measuring HbA 1c values was the quantitative colorimetric determination of glucohemoglobin in whole blood by Stanbio Laboratory.
Expected values range as follows: non-diabetic, normal range (4.2-6.2%); diabetic, good control (5.5-6.8%), fair control (6.8-7.6%) and poor control (above 7.6%).
Statistical analysis
Results were analyzed using the w 2 test. The P-value and the s.d. were also calculated. P-value o0.05 was considered to be significant. 10 
Results
On hundred male diabetic patients met the exclusion criteria. All patients had diabetes type 2 and their ages ranged between 35 and 50 years. The patients included were further divided, according to their degree of glycemic control, into three groups: Group (A): good control (26) patients, Group (B): fair control (9) patients and Group (C): poor control (65) patients. Evaluation of the sexual function (including potency and ejaculation) was carried out by asking the patients to complete questions from the International Index of Erectile Function questionnaire. The results obtained were classified, as regards potency, according to the score into Group (1): good potency (15) patients, Group (2): fair potency (12) patients and Group (3): poor potency (73) patients.
Our data stated that, in the group with good glycemic control, the greater percentage of patients had good potency (53%), whereas a lesser percentage had fair potency (20%) and poor potency (26%). In the group of fair glycemic control, half of the patients had poor potency, and the other half had good (25%) and fair potency (25%). Although in the group with glycemic control the greater percentage of patients was from the group with poor potency (75%) and the lesser percentage was from the groups with good (20%) and fair potency (5%), there was also an association between the degree of potency and glycemic control (P ¼ 0.002) (Figure 1) .
Our results showed that in patients with good potency, the mean level of HbA 1c was 7.9%; in patients with fair potency, the mean level of HbA 1c was 8.2%, whereas in patients with poor potency, the mean level of HbA 1c was 11%. On comparing the mean levels of HbA 1c in different potency degrees, there was a statistically significant difference (P ¼ 0.003) ( Table 1) .
Discussion
Erectile dysfunction is frequently observed in diabetic patients. In diabetic men, ED severity Figure 1 An association was found between the degree of glycemic control in different potency groups (P ¼ 0.002). Erectile function in men with diabetes type 2 H Awad et al increases with age and diabetes duration, poor glycemic control, presence of microvascular complications and cardiovascular disease. Therefore, the clinicians should take preventive measures including undertaking early screening and treatment in high-risk patients. 11 Also, the occurrence of symptoms of depression, anxiety, panic and forgetfulness are unexpectedly common and may also have a role in ED associated with diabetes. 12 As type 2 diabetes may be present for several years before diagnosis, many patients have already developed diabetic complications. Earlier detection and treatment may reduce this burden. 13 Diagnostic criteria based on fasting blood sugar criteria are relatively insensitive in the detection of early type 2 diabetes in at-risk subjects. HbA1c measurement improves the sensitivity of screening in high-risk individuals.
14 The results of our study showed that the level of HbA 1c is significantly higher with declining degrees of potency. Our results showed that in patients with good potency, the mean level of HbA 1c was 7.9%; in patients with fair potency, the mean level of HbA 1c was 8.2%, whereas in patients with poor potency the mean level of HbA 1c was 11%. On comparing the mean levels of HbA 1c in different potency degrees, there was a statistically significant difference (P ¼ 0.003).
Our results were confirmed from the study of Romeo et al. They too had performed a similar study on 78 male patients with diabetes type 2. The mean HbA1c and the mean of erectile function score (of the questions 1-5 of the International Index of Erectile Function) were calculated for each patient. The results they obtained showed that as the degree of glycemic control declines, the degree of potency also declines. They concluded that the mean erectile function score decreased as HbA 1c increased (P ¼ 0.002). Both our study and the study of Romeo et al suggest that glycemic control is independently and inversely associated with the level of ED in men with diabetes type 2. Both studies used a validated questionnaire that assesses the positive relationship between HbA 1c and the history of erectile dysfunction found in the study of Klein et al, goes hand in hand with a study performed by Jamieson et al. 15 Jamieson et al conducted a survey of 142 type 1 diabetic males, of whom 76 (54%) had ED. By using a multivariate analysis, a significant association between ED and glycemic control, as assessed by HbA 1c (P ¼ 0.003), was documented. These data suggest a possible benefit of tight glycemic control in the prevention of erectile dysfunction. Our results were also consistent with the results of Lu et al, 16 who evaluated the association of glycemic control with risk of ED in type 2 diabetics. A selfadministered questionnaire was obtained from 792 subjects with type 2 diabetes. Their results showed that out of 792 subjects, 83.6% reported having ED and 43.2% had severe ED. The HbA 1c level (%) was significantly associated with ED (odds ratio (OR) 1.12, 95% confidence interval (CI): 1.01-1.25). For the risk of severe ED, compared with no and mild to moderate ED, the HbA 1c level was an independent risk factor among the younger group.
One of the possible limitations of our results is the small number of the good potency (15) patients and fair potency (12) patients.
Conclusion
Our findings suggest that glycemic control is independently and inversely associated with ED in men with diabetes type 2. More studies with a larger number and longer duration of follow up are required to confirm these results. Moreover, the authors strongly recommend the documentation of these results by different study designs, for example, controlling diabetes in ED diabetic patients for different periods of time 3-6-9-12-24 months and documenting if this alone is enough to reverse the ED.
